The Evolution of Clinical Trial Operating Systems

Introduction

In 2024, the Tufts Center for the Study of Drug Development published updated figures on what it actually costs to run a Phase III trial. The Tufts CSDD white paper, drawing from an empirical analysis of 409 clinical trial budgets, reported Phase III trials as the most expensive by phase, at $55,716 per day in direct operating costs ^[1]. Across Phase II and Phase III combined, the mean direct cost was approximately $40,000 per day ^[1a]. Every day a site sits inactive before activation, every week a protocol amendment is processed, every month a trial drags past its original timeline: these delays compound against a number that was already difficult to absorb.

What that figure does not capture is how much of the cost is attributable not to science but to infrastructure. The systems used to design, launch, and run clinical trials were not built as a coherent whole. They were assembled over three decades, layer by layer, by organizations solving immediate problems without a shared blueprint. The result is a patchwork of clinical trial management systems, electronic data capture platforms, randomization tools, trial master files, and patient-facing applications that are nominally "integrated" but operationally fragmented.

The conversation in the industry has shifted. Where clinical operations teams once asked "which CTMS should we use," many are now asking a harder question: what would it look like if clinical trials ran on a unified platform that functions, in a practical sense, like an operating system for study execution? That phrase, "clinical trial operating system", is an emerging infrastructure and product-category framing, not a formal regulatory term. But it describes something real: the desire for a single environment where protocol design, site activation, data capture, regulatory document generation, and patient eligibility assessment share a common data model rather than requiring constant manual translation between disconnected systems.

The answer to that question requires understanding how the current infrastructure came to be, where it falls short, and what the emerging generation of AI-native platforms is trying to do differently.

Why Clinical Trial Infrastructure History Matters Now

Framing this as a historical question might seem academic. It is not. The design choices made in the 1990s and 2000s are actively constraining what sponsors and CROs can do today. Technical debt in clinical systems is not metaphorical. It costs money, delays trials, and in some cases compromises the quality of evidence submitted to regulators.

A 2022 Tufts CSDD follow-up study, published in Therapeutic Innovation & Regulatory Science, found that 76% of Phase I through Phase IV protocols now require at least one amendment, up from 57% in 2015 ^[2]. The mean number of amendments per protocol climbed 60% over the same period to 3.3 ^[2]. Each substantial amendment to a Phase III protocol carries a median direct cost of $535,000 ^[3], and that figure excludes the operational ripple effects: site re-training, IRB resubmission cycles, patient reconsent, and enrollment disruption.

Many of these protocol amendments trace back to protocol design decisions that a better-connected system would have caught earlier. When the teams writing the protocol, building the EDC study, activating sites, and managing patient eligibility operate across separate systems that do not share a common data model, errors that span those boundaries go undetected until they become amendments. The infrastructure problem and the protocol quality problem are the same problem.

Understanding how this fragmentation happened is the first step toward building something better.

Three Eras of Clinical Trial Technology

Era One: Paper and Early Digitization (Pre-2000)

Before purpose-built software existed, clinical trials ran on paper. Investigators maintained paper case report forms, regulatory binders filled with original source documents, and manually reconciled enrollment logs. Monitoring meant traveling to a site, sitting with a stack of patient records, and checking each entry against the case report form by hand. The process was slow, error-prone, and impossible to audit in real time.

The first wave of digital tools targeted data capture. Electronic data capture systems began appearing in the 1990s, offering sponsors a way to collect trial data without waiting for physical CRF shipments. Clinical trial management systems emerged at roughly the same time, providing a centralized digital environment for managing and tracking clinical research activities, including study subject management, regulatory compliance, reporting, budgeting, and sponsor invoicing ^[4]. These were genuine improvements over paper. They were also designed independently, by different vendors, to solve different problems, with no expectation that they would ever need to communicate with each other.

The regulatory context of that period reinforced the compartmentalization. ICH E6, finalized in 1996 ^[5], established good clinical practice standards for investigator and sponsor responsibilities, monitoring, reporting, and archiving. It described the obligations without prescribing a specific technical architecture for fulfilling them. Organizations met those obligations with whatever systems they had.

Era Two: Siloed eClinical Ecosystems (2000 to 2018)

As trials grew more complex, spanning more countries, more sites, and more patient populations, the number of specialized tools multiplied. By the early 2010s, a typical global Phase III trial operated across a CTMS for operational oversight, an EDC system for data capture, a randomization and trial supply management platform for treatment assignment, an electronic trial master file for regulatory document storage, and ePRO tools for capturing participant data outside the clinic. CDISC's Digital Data Flow documentation describes the USDM as serving downstream consumers that include EDC, CTMS, trial master file, protocol authoring, CSR, and statistical analysis plan systems, with APIs and FHIR-based interoperability supporting broader data exchange across the ecosystem ^[10]. Safety and pharmacovigilance ran on separate infrastructure still. Laboratory data came through yet another channel.

Each of these systems was validated independently. Each had its own access controls, audit trail structure, and data model. When study teams needed information that crossed system boundaries, the answer was usually a manual reconciliation process: someone exported a report from one system, compared it against a report from another, and documented the comparison in a spreadsheet.

An institution operating a centralized CTMS described the environment it replaced as "a collection of disparate systems, databases and document management tools" used for managing study subjects, regulatory compliance, reporting, sponsor invoicing, and research administration, each handling a fragment of the research workflow in isolation ^[7]. That description would have been familiar to many large research organizations for most of this era.

Era Three: Toward Integration and Convergence (2018 to Present)

The limitations of siloed infrastructure became harder to ignore as two pressures converged. First, trial complexity continued to increase. More endpoints, more countries, more decentralized elements, and more adaptive designs created coordination demands that manual reconciliation could not meet. Second, regulators began providing clearer frameworks for what integrated digital trial conduct should look like, including risk-proportionate monitoring expectations under ICH E6(R3) ^[5], which reached Step 4 adoption on January 6, 2025 ^[8].

Vendors responded in two ways. Some built tighter point-to-point integrations between their own products, creating unified suites where a single vendor supplies CTMS, EDC, RTSM, and eTMF. Others pursued open API architectures intended to allow cross-vendor data exchange without forcing organizations into a single-vendor stack. Neither approach fully resolved the underlying problem, which is not the absence of integrations but the absence of a shared study definition that all downstream systems can consume from a single authoritative source.

That shared definition is what the current generation of standards work is trying to create. It is worth noting that USDM and DDF implementation maturity varies considerably across vendors and sponsors, and full automation of protocol-to-system data flow remains an ongoing aspiration rather than a deployed reality across the industry as of 2026.

The Protocol as Infrastructure: USDM, ICH M11, and Digital Data Flow

The most consequential shift happening in clinical trial technology today is not a new software product. It is a change in how clinical protocols are authored and transmitted.

Today's workflow is document-centric. A sponsor authors a protocol as a Word document. That document is then manually transcribed into an EDC study build, a CTMS configuration, a site startup package, and a patient eligibility assessment. Each transcription introduces the possibility of error. A criterion described one way in the protocol can appear slightly differently in the EDC edit check, and slightly differently again in the site training manual. Inconsistencies of this kind are a documented source of avoidable amendments ^[3].

TransCelerate Biopharma and CDISC described the alternative clearly in their Digital Data Flow initiative: the goal is a "write once, read many" model, where a protocol authored in a standardized machine-readable format flows automatically into consuming systems without manual re-entry ^[9]. The vehicle for that standardization is the Unified Study Definitions Model (USDM), an open-source data model first developed in 2021 and now aligned with ICH M11 ^[10].

To make this concrete: consider an inclusion criterion specifying a minimum HbA1c value for a diabetes trial. In today's document-centric workflow, that criterion is typed into the protocol narrative, then separately entered as an edit check threshold in the EDC system, then described again in the site eligibility checklist, and then interpreted again by the patient pre-screening team. Four separate representations of the same rule, each requiring a human to ensure they agree. Under the USDM model, and this example is illustrative of the USDM structuring concept, not a quoted implementation from CDISC, that criterion would be authored once as a structured data object with a defined type, value, unit, and relationship to the study population. Via API, that object flows directly to the EDC system, the CTMS enrollment configuration, and the eligibility screening tool, without any of the intermediate transcription steps ^[9],[10].

ICH M11 is the Clinical Electronic Structured Harmonised Protocol (CeSHarP) initiative that provides the governance layer for this approach. The ICH Assembly first endorsed the draft guideline in September 2022 ^[11]. The technical specification underwent a second public consultation in March 2025 ^[12]. FDA published the final guidance in the Federal Register on May 22, 2026 ^[13]. The EMA adopted the guideline at Step 5 in parallel ^[14]. The guidance describes an internationally harmonized standard for protocol content and electronic exchange, with standardized data fields and terminologies designed to enable interoperable transmission across regulatory regions ^[13].

When the USDM and ICH M11 technical specification are implemented by downstream systems, the effect would be significant. A protocol structured according to the standard could be read directly by an EDC system to auto-populate study builds, by a CTMS to configure enrollment milestones, and by a regulatory submission tool to pre-populate common document sections.

What Does Not Change: Sponsor Accountability and Human Oversight

Before examining the technology implications further, it is worth being direct about what new infrastructure does not alter.

Sponsors retain full responsibility for trial design quality, protocol content, regulatory submission accuracy, vendor qualification, and participant safety regardless of which systems are used to execute those functions ^[5],[6]. An AI system that generates a protocol section, a USDM-structured data object that auto-populates an EDC edit check, or a FHIR-connected tool that flags a potentially eligible patient: none of these change who is accountable for the output. Validation of computerized systems used in regulated clinical trial contexts remains the sponsor's obligation under 21 CFR Part 11 ^[15] and ICH E6(R3) ^[8]. The infrastructure evolves; the oversight requirement does not.

A related consideration worth flagging: unified suites, best-of-breed API approaches, and USDM-native platforms each create different validation and vendor-oversight burdens. A sponsor choosing a single-vendor unified suite inherits that vendor's validation documentation framework; a sponsor assembling a best-of-breed stack must manage validation and integration qualification across each component independently. Neither approach removes the validation obligation, it only changes where the work sits.

Operational Implications: What Fragmentation Actually Costs

The gap between where the industry is and where these standards aspire to bring it is worth measuring concretely.

Consider protocol amendments. A 2022 Tufts CSDD study found that the mean number of amendments per protocol had increased 60% since 2015, reaching 3.3 per protocol across Phase I through Phase IV ^[2]. The 2015 study found that 45% of amendments were avoidable ^[3], attributable to protocol design flaws, inconsistencies in the protocol narrative, and infeasible eligibility criteria. In the 2022 follow-up, 77% of amendments were classified as unavoidable, with regulatory agency requests and changes to study strategy as the top reasons ^[2]. That shift suggests both that the design problem persists and that the operating environment has become more volatile, putting more pressure on systems to handle change efficiently.

Fragmented systems handle change poorly. When a protocol amendment requires updating an eligibility criterion, that change must propagate through the EDC edit check, the patient pre-screening workflow, the site training material, the ICF, and the CTMS enrollment configuration. Without a shared data source, each update is a separate manual task.

Enrollment performance sits downstream of all of these factors. A 2012 Tufts CSDD study found that 41% of activated investigative sites in Phase II and Phase III trials failed to reach their target enrollment numbers ^[16]. Separately, a McKinsey analysis of decentralized trial adoption, attributing the figure to a Sanofi analysis, found that approximately 70% of potential trial participants live more than two hours from the nearest trial site, making geography one of the structural barriers to site-based enrollment ^[17]. These figures reflect a system in which site selection, patient identification, and operational readiness are managed across disconnected tools with limited ability to share signals before problems become enrollment shortfalls.

How Different Approaches to Infrastructure Compare

The following table clarifies the distinctions between how clinical trial technology has been organized across different eras and architectural approaches. These are not formal regulatory categories; they are descriptive terms used in the industry to distinguish the scope and integration model of different platform types.

The last row describes where the industry is heading. Few, if any, platforms fully implement all of it today. The USDM and ICH M11 standards provide the framework; platform adoption is an ongoing process across the vendor ecosystem ^{[9],[10],[13]}.

One distinction worth drawing for readers familiar with CDISC submission standards: USDM and DDF operate at the protocol-design and study-definition level, governing how study intent flows into operational systems before data collection begins. They are separate from CDISC SDTM and ADaM, which govern how collected clinical data are structured for regulatory submission after a trial completes. The two layers are complementary, not interchangeable.

Regulatory and Documentation Considerations

Two regulatory documents are directly shaping how the next generation of clinical trial infrastructure will need to be built.

The first is ICH E6(R3), adopted at Step 4 on January 6, 2025 ^[8]. The EMA's effective date for compliance was July 23, 2025 ^[14a]. The guideline introduced a risk-proportionate monitoring framework, clarifying that sponsors must apply a quality management system approach to trial conduct and that monitoring strategies should be calibrated to the actual risk profile of each study ^[8]. That expectation is difficult to fulfill across siloed systems that do not surface a unified view of site performance, data quality, and protocol deviation patterns in real time.

The second is FDA's final guidance on conducting clinical trials with decentralized elements, published on September 18, 2024, finalizing a draft issued in May 2023 ^[6]. The guidance affirmed that FDA's regulatory requirements apply equally to decentralized trials and traditional site-based trials ^[6]. Sponsors must document the origin, flow, and handling of data collected from all sources in a decentralized trial, including data collected at participants' homes, through local healthcare providers, and via digital health technologies ^[6]. For organizations running decentralized elements on systems that were designed before remote data acquisition was operationally common, that documentation requirement creates a significant compliance burden.

For AI-generated content and AI-assisted workflows specifically, FDA issued a draft guidance on January 7, 2025 (docket FDA-2024-D-4689) on the use of artificial intelligence to support regulatory decision-making for drug and biological products ^[18]. The draft frames AI credibility in terms of a risk-based assessment framework tied to the specific context of use. Any AI output intended to inform a regulatory submission must be validated, auditable, and accompanied by documentation of the AI system's role in generating it. 21 CFR Part 11 requirements for electronic records and audit trails apply to computerized systems used in regulated clinical trial contexts ^[15]. Whether Part 11 applies to a specific AI tool depends on the nature of the records it creates or modifies in that context, not on whether the tool is described as AI-powered.

AI and Automation in the Clinical Trial Stack

The promise of AI in clinical trial operations is not primarily about speed. It is about the ability to detect and act on patterns that would be invisible to teams working across disconnected systems.

In the document generation context, a 2025 preprint evaluation found that an optimized LLM-based system for ICF drafting achieved near-100% compliance with 18 regulatory rules derived from FDA guidelines, and attained over 90% factual accuracy when integrated with human review, compared to 57% to 82% for an unoptimized baseline model ^[19]. That evaluation covered one specific benchmark task (informed consent form drafting from protocol inputs) and should not be generalized to other regulatory document types without separate validation. The broader finding is that AI systems applied to regulatory document generation can perform well on compliance metrics when properly designed, and human review remains necessary to achieve acceptable factual accuracy in a regulated context.

For site selection, AI-assisted approaches can draw on historical enrollment performance data, site infrastructure characteristics, and patient population metrics to forecast site-level enrollment probability before a contract is signed. For patient pre-screening, FHIR-connected systems can evaluate structured EHR data against protocol eligibility criteria at scale, identifying potentially eligible patients who would never have been surfaced through manual chart review. Both use cases depend on connectivity. An AI layer sitting on top of disconnected infrastructure does not resolve the underlying data access problem; it inherits it.

A further consideration is validation. FDA's draft guidance FDA-2024-D-4689 introduced a risk-based credibility assessment framework for AI used to support regulatory decision-making ^[18]. Organizations deploying AI in these contexts should validate those systems for their specific intended use and document that validation before relying on AI outputs in any regulated context.

How Kitsa Fits Into This Problem

The problem this article describes, fragmented infrastructure that forces manual reconciliation between protocol design, site operations, and document generation, is precisely what Kitsa was built to address. KScribe, Kitsa's AI-native regulatory document generation platform, produces protocols, informed consent forms, investigator brochures, DSURs, and clinical study reports from a connected document environment where cross-document consistency is maintained computationally rather than by hand. KScout supports site selection using data-driven feasibility analysis. KScreener uses FHIR-connected workflows to evaluate patient eligibility against structured protocol criteria. Together, these tools are designed for the moment when the industry's infrastructure finally begins to function as a system rather than as a collection of separately validated parts.

Key Takeaways

• Clinical trial management systems originated in the 1990s as standalone tools designed to solve specific operational problems, not as components of a coordinated ecosystem. Three decades of layered additions produced the siloed eClinical infrastructure that many large organizations operate today.
• A 2024 Tufts CSDD analysis found that Phase III trials carry the highest direct daily operating cost by phase at $55,716, while the mean across Phase II and Phase III combined is approximately $40,000 per day, making infrastructure-driven delays among the most expensive inefficiencies in drug development ^[1],[1a].
• Protocol amendment rates climbed from 57% of protocols in 2015 to 76% in a 2022 Tufts CSDD study, with each substantial Phase III amendment carrying a median direct cost of $535,000 ^[2],[3].
• ICH M11 CeSHarP, finalized by FDA in the Federal Register on May 22, 2026, establishes an internationally harmonized standard for electronic protocol content and exchange, directly enabling the "write once, read many" architecture that CDISC's Digital Data Flow initiative and the USDM are designed to support ^[13],[9].
• FDA's September 2024 final guidance on decentralized clinical trial elements requires sponsors to document data origin, flow, and handling from all sources, a requirement that is difficult to fulfill with disconnected infrastructure ^[6].
• AI tools that create, modify, maintain, or transmit regulated electronic records in clinical trial contexts remain subject to 21 CFR Part 11 expectations and ICH E6(R3) quality management requirements regardless of how they are branded. Validation for the specific intended use is required before AI outputs can be relied on in a regulatory submission ^[18],[15].
• The transition from a collection of separate systems toward a unified clinical trial infrastructure is a standards problem as much as a technology problem. USDM and ICH M11 are among the most consequential infrastructure developments the industry has produced in two decades ^[9],[13].

FAQ

References

1. [1]Smith ZP, DiMasi JA, Getz KA. "Quantifying the Value of a Day of Delay in Drug Development." Tufts CSDD White Paper. August 2024. https://csdd.tufts.edu/sites/default/files/2025-02/Aug2024%20Day%20of%20Delay%20White%20Paper%20Final.pdf
2. [1a]Smith ZP, DiMasi JA, Getz KA. "New Estimates on the Cost of a Delay Day in Drug Development." Therapeutic Innovation & Regulatory Science. 2024;58(5):855-862. https://doi.org/10.1007/s43441-024-00667-w
3. [2]Getz KA, et al. "New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance." Therapeutic Innovation & Regulatory Science. 2024. https://doi.org/10.1007/s43441-024-00622-9
4. [3]Getz KA, Stergiopoulos S, Short M, et al. "The Impact of Protocol Amendments on Clinical Trial Performance and Cost." Therapeutic Innovation & Regulatory Science. 2016;50(4):436-441. https://doi.org/10.1177/2168479016632271
5. [4]Institute of Translational Health Sciences / Fred Hutch Cancer Center. "CTMS Program Office: What Is a Clinical Trial Management System?" https://www.iths.org/ctms/what-is-a-clinical-trial-management-system/
6. [5]International Council for Harmonisation. "ICH E6: Efficacy Guidelines." https://www.ich.org/page/efficacy-guidelines
7. [6]U.S. Food and Drug Administration. "Conducting Clinical Trials With Decentralized Elements: Guidance for Industry, Investigators, and Other Interested Parties." September 2024. https://www.fda.gov/media/167696/download
8. [7]Institute of Translational Health Sciences / Fred Hutch Cancer Center. "CTMS Program Office: Overview." https://www.iths.org/ctms/what-is-a-clinical-trial-management-system/
9. [8]International Council for Harmonisation. "ICH E6(R3) Guideline for Good Clinical Practice." Step 4 Final Guideline, adopted January 6, 2025. https://database.ich.org/sites/default/files/ICH_E6(R3)_Step4_FinalGuideline_2025_0106.pdf
10. [9]TransCelerate Biopharma / CDISC. "Digital Data Flow: Write Once, Read Many." 2024. https://www.transceleratebiopharmainc.com/assets/digital-data-flow-solutions/
11. [10]CDISC. "Digital Data Flow and the Unified Study Definitions Model (USDM)." https://www.cdisc.org/ddf
12. [11]Federal Register. "M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP)." 87 FR 78696. December 22, 2022. https://www.federalregister.gov/documents/2022/12/22/2022-27823
13. [12]Federal Register. "M11 Technical Specification: Clinical Electronic Structured Harmonised Protocol." 90 FR 24146. June 6, 2025. https://www.federalregister.gov/documents/2025/06/06/2025-10359
14. [13]Federal Register. "M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability." FR Doc. 2026-10295. May 22, 2026. https://www.federalregister.gov/documents/2026/05/22/2026-10295/m11-clinical-electronic-structured-harmonised-protocol-cesharp-international-council-for
15. [14]European Medicines Agency. "ICH M11 Guideline on Clinical Electronic Structured Harmonised Protocol (CeSHarP) Step 5." EMA/CHMP/ICH/778799/2022. https://www.ema.europa.eu/en/ich-m11-guideline-clinical-study-protocol-template-technical-specifications-scientific-guideline
16. [14a]European Medicines Agency. "ICH E6(R3) Guideline for Good Clinical Practice Step 5." EMA/CHMP/ICH/135/1995. Date for coming into effect: July 23, 2025. https://www.ema.europa.eu/en/documents/scientific-guideline/ich-e6-r3-guideline-good-clinical-practice-gcp-step-5_en.pdf
17. [15]U.S. Food and Drug Administration. "21 CFR Part 11: Electronic Records; Electronic Signatures." Code of Federal Regulations. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-11
18. [16]Applied Clinical Trials / Tufts CSDD. "Enrollment Performance: Weighing the 'Facts'." Tufts CSDD 2012 study data. https://www.appliedclinicaltrialsonline.com/view/enrollment-performance-weighing-facts
19. [17]McKinsey & Company. "No Place Like Home? Stepping Up the Decentralization of Clinical Trials." June 2021. (McKinsey attributes the 70% figure to a Sanofi analysis.) https://www.mckinsey.com/industries/life-sciences/our-insights/no-place-like-home-stepping-up-the-decentralization-of-clinical-trials
20. [18]U.S. Food and Drug Administration. "Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products." Draft Guidance. Docket FDA-2024-D-4689. January 7, 2025. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological
21. [19]Weng Y, et al. "InformGen: An AI Copilot for Accurate and Compliant Clinical Research Consent Document Generation." arXiv preprint. April 2025. https://arxiv.org/pdf/2504.00934